The Behavior Of I-Mab (IMAB) Stock Is Not As Predictable As You Think

view original post

I-Mab (NASDAQ:IMAB) concluded the trading at $9.52 on Friday, June 10, with a fall of -7.57% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $10.30 and 5Y monthly beta was reading 0.82 with its price kept floating in the range of $9.405 and $10.43 on the day. Considering stock’s 52-week price range provides that IMAB hit a high price of $85.40 and saw its price falling to a low level of $8.05 during that period. Over a period of past 1-month, stock came subtracting -9.42% in its value.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


With its current market valuation of $783.12 million, I-Mab is set to declare its quarterly results on Aug 31, 2021. Analysts are in estimates of $0 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to $0 for 2020 with estimates of that growing to -$1.67 in next year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review IMAB stock’s current outlook then short term indicators are assigning it an average of 100% Sell, while medium term indicators are categorizing the stock at an average of 100% Sell. Long term indicators are suggesting an average of 100% Sell for it.

Digging deeper we become aware of the PEG ratio of the IMAB stock which is currently positioned at 0. It further provides that stock’s current price level is -8.20% away from its 20-day simple moving average and is -24.09% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 43.48 while volatility remained at 12.43% over the past week which changes to 11.81% when measuring it over the past month. Average true range or ATR is currently at 1.19. In predicting price targets of as low as $35.00 and as high as $103.00, analysts are in agreement on assigning the stock over the next 12 months average price target of $70.81. Stock’s current price level is -267.65% above from estimated low price target while it is -981.93% below the estimated high; and even if the IMAB’s share succeeded to reach the median price of $74.00, then the outlook of -677.31% could come to the excitement of the investors.

In comparing I-Mab (IMAB)’s stock with other industry players reveals that stock’s current price change of -7.57% and that of -86.74% over the past 12 months is in competing position with that of Johnson & Johnson (JNJ) which saw its stock price fall by -0.67% in the last trading and went through an increase of 4.60% in past 12-month trading. Industry’s another major player Pfizer Inc. (PFE) has fall -3.50% down in previous session, but over the past year has faced a rise of 24.46%, while Eli Lilly and Company (LLY) was also down -2.06% however its price remained floating in the green at 32.54% over the same period. I-Mab has a P/E ratio of 0 against that of Johnson & Johnson’s 23.24 while Pfizer Inc. is showing 11.27 for the same. On the other hand, the S&P 500 Index was down -2.91% in the last trading session while the Dow Jones Industrial closed the session lower at -2.73%.

Having a second look at I-Mab (NASDAQ:IMAB) provides that stock’s average daily trading volume for 3 months was 1.47 million, while it jumped to 1.91 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 78.52 million.

The percentage of outstanding shares held by the insiders is 1.07% while it is 58.20% for the institutional holders. The figures also indicate that as of Apr 28, 2022, number of stock’s short shares was 4.06 million which implies a short ratio of 2.28. This shows up a 4.91% of Short Interest in company’s outstanding shares on the day. In April the standing of shares short improved as it was 3.86 million in the previous month. Subtraction of -79.91% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.